ORIGINAL RESEARCH article

Front. Neurol.

Sec. Endovascular and Interventional Neurology

Volume 16 - 2025 | doi: 10.3389/fneur.2025.1573247

This article is part of the Research TopicVascular Diseases of the Brain: Insights, Progress and Lessons LearnedView all 6 articles

Abciximab in rescue therapy of thromboembolic events during endovascular treatment of cerebral aneurysms: single center experience of 49 cases

Provisionally accepted
Lukas LenhartLukas Lenhart1*Valentin LadenhaufValentin Ladenhauf1Verena RassVerena Rass2Stephanie A TreichlStephanie A Treichl3Ronny BeerRonny Beer2Christian F. FreyschlagChristian F. Freyschlag3Elke R GizewskiElke R Gizewski1Astrid GramsAstrid Grams1
  • 1Department of Radiology, Innsbruck Medical University, Innsbruck, Tyrol, Austria
  • 2Department of Neurology, Innsbruck Medical University, Innsbruck, Tyrol, Austria
  • 3Department of Neurosurgery, Innsbruck Medical University, Innsbruck, Tyrol, Austria

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Background: The aim of this study was to assess the safety and effectiveness of abciximab (ReoPro®), a glycoprotein-IIb/IIIa receptor antagonist, in the management of thromboembolic complications during endovascular treatment of intracranial aneurysms.Methods: From an inhouse data base of 218 coil embolisations in 178 patients with cerebral aneurysms (median age 57 years, 72% females) -among them 53 interventions with subarachnoid hemorrhage (SAH) requiring acute endovascular treatment, and 165 with elective endovascular treatment of unruptured aneurysmswe retrospectively reviewed 53 interventions that received abciximab during endovascular treatment, and diffusion-weighted imaging after endovascular treatment (median 7 days after intervention, range 5 to 9 days). Four subgroups were identified, (i) SAH patients with abciximab (SAH-Ab, n=18), (ii) SAH patients without abciximab (SAH-no, n=35), (iii) elective patients with abciximab (El-Ab, n=31), and (iv) elective patients without abciximab (El-no, n=134) treatment. Angiographic success of clot dissolution, post-interventional occurrence of intracranial hemorrhages and the modified Rankin Scale (mRS) pre and six months after endovascular treatment were recorded. Brain tissue infarction-load was categorized as: no, punctual (<500 mm 2 ), small (500-1000 mm 2 ) and large (>1000 mm 2 ) infarctions.Results: Complete and partial angiographic success was achieved in 94% of cases.

Keywords: Abciximab, Endovascular neuroradiology, Intracranial Aneurysm, Thromboembolic complication, Cerebral Infarction, intracerebral hemorrhage

Received: 08 Feb 2025; Accepted: 11 Jun 2025.

Copyright: © 2025 Lenhart, Ladenhauf, Rass, Treichl, Beer, Freyschlag, Gizewski and Grams. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lukas Lenhart, Department of Radiology, Innsbruck Medical University, Innsbruck, 6020, Tyrol, Austria

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material